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assess the factors inﬂuencing annual treatment costs. Logistic
regression analysis was conducted to assess the association
between obesity and related clinical factors. RESULTS: A total of
341 (3.4%) children or adolescents received an obesity diagnosis
during the study period. The average annual treatment costs were
$7481 (SD  8371) for patients experiencing obesity and $5364
(SD  15,322) otherwise. A total of 4204 (42.5%) patients
received atypical antipsychotics, 2237 (22.6%) with lithium, and
5890 (59.5%) with other anticonvulsants. Being obesity is asso-
ciated with atypical antipsychotic use (odds ratio [OR] = 1.49,
95% conﬁdence interval [CI] 1.18–1.88), and key comorbidities
like diabetes mellitus (OR = 3.40, 95%CI 1.96–5.89) and hyper-
tension (OR = 4.41, 95%CI 2.70–7.20). Higher treatment cost is
associated with the use of atypical antipsychotics (p < 0.0001),
hospitalization (p < 0.0001), ER visit (p < 0.0001), and some key
comorbidities like diabetes mellitus (p < 0.0001) and substance
abuse disorder (p < 0.0001). CONCLUSION: Higher treatment
costs are associated with obesity in children or adolescents with
bipolar disorder. Metabolic complications should be considered
by clinical practitioners when prescribing medication in this
population.
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Lee SM, Nam MH,Yoon SH, Kim BY, Choi MR, Cho HS, Lee KD
Health Insurance Review & Assessment Services, Seoul, South Korea
Organization: Health Insurance Review & Assessment Services
(HIRA), Seoul, Korea.
Problem or Issue Addressed: Policy makers of Korean govern-
ment decided to increase the rate of public expenditure on health
per total expenditure on health (coverage rate) in the patients
with cancer. There had been conﬂicts between health care pro-
viders and decision makers of health insurance in the use of
off-label anticancer drug.
Goals: (1)Stepwise increase coverage rate of the patients with
cancer; (2)Rational control of off-label drug use related to treat-
ment of cancer including chemotherapeutic drugs and drugs for
cancer pain; (3)To control the reimbursement for the patients
with cancer in the limited budget allocation.
Outcomes items used in the decision: Safety and effectiveness
data from the literature and cost of drug.
Implementation Strategy: A Project to enhance coverage rate of
treatment of cancer started in September, 2005. The project
consists of the registry of the patients with cancer, and the special
committee for review of drugs related to treatment of cancer. The
handouts for the meetings have been made according to the
‘evidence based review manual’ which had been made by evi-
dence based health care team of HIRA. It is systematic approach
to retrieve information related to the safety and effectiveness
about the drugs. The rate of the patient’s payment per beneﬁt
schedule is reduced from 20% to 10%.
Results: The total number of patients whose medical fees were
claimed by health care provider was 42.8 million in 2005 and it
was 43.4 million in 2006 increased by 1.4%. The total number of
patients with cancer among them was 670 thousands in 2005
and it was 710 thousands in 2006, increased by 6.0%. The rate
of public expenditure on health per total expenditure on health in
the patients with cancer increased from 49.6% to 71.0%. The
rate of patients taken with anticancer chemotherapy increased
from 5.9% to 7.9%. The expected allocated budget was 597
million $ and the actual spending money was 524 million $. The
conﬂicts about off-label drug use have decreased.
Lessons Learned: The project was performed successfully by
evidence based decision making process and reasonable use of off
label drug use.
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Organization: Center for Drug Policy, Partners Healthcare.
Problem or Issue Addressed: The Pharmacy Cost Management
Committee of the Partners Healthcare System (PHS), a consor-
tium of seven greater Boston area hospitals, has recognized the
need to control the future growth rate of pharmaceuticals by
managing the utilization of new, high cost pharmaceutical tech-
nologies and learning from best practices across the network and
country. The Center for Drug Policy (CDP) was established in
August 2007 to provide the analytical resources to support the
Pharmacy Directors and multidisciplinary teams of physician and
pharmacist content experts in this endeavor.
Goals: The major objectives of the CDP are to forecast and
manage the introduction of new, high cost pharmaceutical tech-
nologies and to streamline the development and implementation
of common guidelines across the network. Additional objectives
of the CDP are to 1) identify and coordinate cost savings oppor-
tunities, 2) conduct prospective utilization reviews and assess-
ment, 3) share best practices across the network, and 4)
benchmark against high performance organizations nationwide.
Outcomes items used in the decision: Both process and outcome-
related measures will be measured. For process-related measures,
the number of the following outputs and select intermediate
steps will be assessed quarterly: guidelines (drug/therapeutic
class/disease), budget-impact models, guideline dissemination
and implementation, and assessment of guideline impact.
Outcome-related measures will be assessed at a global level and
a project-speciﬁc level. At the global level, annual drug pur-
chases, drug cost/case-mix adjusted discharge, and drug cost/
case-mix adjusted patient day will be measured quarterly at each
hospital. At a project-speciﬁc level, outcomes will depend on the
pharmaceutical technology but would include clinical (e.g.,
adherence to guidelines, time to event, complications, etc.) and
economic measures (e.g., volume of drug, length of stay, drug
purchases, etc.)
Implementation Strategy: To establish the CDP, the CDP leader-
ship met with key stakeholders across the network of hospitals,
undertook a targeted literature review of cost management strat-
egies in the hospital setting, and conducted an on-site visit to
another hospital’s CDP. Access to and training on key data
resources including drug purchasing data, computerized physi-
cian order entry, and cost accounting systems was obtained. A
database to track emerging drug therapies and tools to assist in
project management were created. Internal processes and tools
were developed to ensure quality, consistency, and documenta-
tion of guideline development. To facilitate sharing best practices
across the hospital network, presentation opportunities have
been provided at monthly CDP meetings; in addition, a monthly
memo summarizing key Pharmacy & Therapeutics Committees
activities across the network has been prepared and distributed
to Pharmacy leadership. Templates for ongoing internal report-
ing were also developed.
Results: As the CDP was established in August 2007, data col-
lection is ongoing; an overview of anticipated results is, however,
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provided. Using the internal reporting template, the number of
process-related measures will be presented. For outcome-related
measures, the global metric reporting approach will be described
and a reporting template will be shared. An example of a project-
speciﬁc reporting template will be presented.
Lessons Learned: To date, we have learnt that the key steps
to establishing a new CDP include early involvement of key
clinical expert stakeholders in guideline development, the
need to minimize the burden of these clinical experts, and
involvement of senior leadership as needed to ensure that
progress continues to be made. In addition, collaboration is
important to minimize duplication of effort and to increase the
efﬁciency of the CDP. Finally, developing a plan a priori for
guideline dissemination, implementation, and assessment is
needed.
CASE 6
THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY
TO IMPROVE QUALITY INTHE ACUTE CARE
SETTING
Mutnick AH,Wong PK, Hanseman DJ
Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA
Organization: Mercy Health Partners, Southwest Ohio. The
regional ofﬁce consists of 5 acute care hospitals and 6 Long Term
Care Nursing Homes with over 8000 employees and 2000 phy-
sicians on staff.
Problem or Issue Addressed: The availability of a growing body
of high quality evidence-based practice guidelines has created
exceptional opportunities to maximize the quality of care deliv-
ered to patients. However, are we utilizing the available evidence
in daily practice, or are individual clinician preferences still dic-
tating practice levels? Can evidence-based practice recommenda-
tions be translated into a community-based health care system?
Goals: The provision of evidence-based practice attributes within
a series of designated order sets; The ability to maximize consis-
tency, reduce variability, and to evaluate the delivery of quality
patient care; The ability to build-in practitioner ﬂexibility for
those respective areas, not supported by evidence-based practice;
To utilize an available “evidence-based practice” database, which
is continuously updated, and which allows timely dissemination
of updates across numerous disease entities.
Outcomes items used in the decision: We utilized effectiveness
data as reported in the peer-reviewed literature along with cur-
rently available evidence-based classiﬁcation schemes. Addition-
ally, we utilized the commercially available database, Zynx.
Rates of order set implementation were captured through a
program which allowed us to evaluate the clinical and ﬁnancial
outcomes associated with the newly adopted order sets versus
alternative order sets used by clinicians.
Implementation Strategy: The initial step in our implementation
process occurred when our Healthcare Systems’ Board of Trust-
ees and Physicians Council agreed upon a goal to advance a
culture of quality through evidence based medicine and clinical
transformation during the early spring in 2006. After a series of
meetings held for the systems’ key clinical decision makers, an
initial group of order sets were identiﬁed for review, based on
high use, high costs, and key components of our Core Perfor-
mance Practice Measures. A group of 10 clinical order sets,
which included Community Acquired Pneumonia, Heart Failure,
Chest Pain, Caesarean Section Delivery, Pelvic Delivery, Special
Care Nursery, Newborn Nursery, Deep Vein Thrombosis Pro-
phylaxis, and Erythrocyte Stimulating Factors. Through the con-
sensus process, the clinical leadership adopted an evidence-based
algorithm for our health system, which was subsequently
approved by our Board of Trustees. The algorithm employs select
evidence classiﬁcation schemes currently available in the peer-
reviewed literature. The order sets were all adopted by the health
system. A ﬁnal step in the process was to develop an electronic
data capture instrument, which would allow us to quantify the
implementation rate for each of the order sets that were
approved.
Results: We will share the ﬁnancial and clinical outcomes, which
have been evaluated for our initial order sets as well as select
metrics, which demonstrate the level of acceptance within our
Health System.
Lessons Learned: The initial lesson learned early in our imple-
mentation process was that trying to standardize clinical practice
amongst a large group of physicians throughout a ﬁve-hospital
health care system will occur via an evolutionary process rather
then a revolutionary process. Additionally, we learned that the
development of order sets required two key components, 1) An
evidence-based component based on a high degree of literature-
based recommendations, and 2) A practice-based component,
which utilized clinician-practice experience, not in conﬂict with
evidence-based practice, for those areas not supported by
evidence-based recommendations.
CANCER OUTCOMES RESEARCH
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TRENDS INTREATMENT AMONG ELDERLY COLORECTAL
CANCER PATIENTS INTHE US: EVIDENCE FROM LINKED
SEER-MEDICARE DATA
Lang K1, Lines LM1, Lee DW2, Korn JR1,Vanness DJ3, Earle C4,
Menzin J1
1Boston Health Economics, Inc,Waltham, MA, USA, 2GE Healthcare,
Waukesha,WI, USA, 3University of Wisconsin-Madison, Madison,WI,
USA, 4Harvard University, Boston, MA, USA
OBJECTIVE: This study used linked SEER-Medicare data to
analyze recent treatment patterns and trends among elderly CRC
patients in the US. METHODS: Study cohorts included patients
aged 65+ newly diagnosed with adenocarcinoma of the colon
(CC) or rectum (RC) between 1996 and 2002 (n = 60,916) and
1:1 age/sex/location-matched patients from a Medicare 5%
sample. Cohorts were followed from index until death or Decem-
ber 31, 2005 to evaluate differences in clinical characteristics,
resource use, and initial treatment modalities by cancer site and
stage. To analyze trends, a standardized 3-year follow-up was
used. RESULTS: Mean (SD) age among CRC patients and
controls was 77 (7) years, 46% were male, and 84% were
white. About 28% of patients had rectal cancer. Overall, 7% of
CRC patients were diagnosed at Stage 0, 24% at Stage 1, 28% at
Stage 2, 21% at Stage 3, and 15% at Stage 4 (remainder were
unstaged). Between 1996 and 2002, surgery was the primary
treatment among CC patients (range: 73–78%), followed by
combined surgery/chemotherapy (16–20%), with very little
radiation use (<2%). Among RC patients, surgery was the
primary treatment (range: 53–56%), followed by surgery/
chemoradiotherapy (15–17%), surgery/radiotherapy (8–11%),
surgery/chemotherapy (7–9%) and no treatment (7–11%). CRC
patients used signiﬁcantly (P < .001) more health care resources
than controls in every category, with the largest differences in use
of hospital (23 vs. 12 days), home health (47% vs. 30%) and
hospice (24% vs. 9%). Use of all resources remained steady from
1996 to 2002, with slight declines in use of home health (from
47% to 41%; P < .001) and skilled nursing (from a mean of 9 to
8 days; P = .017) and a slight increase in hospice use (from 16%
to 19%; P < .001). CONCLUSION: Treatment patterns and
resource use among CRC patients remained steady between 1996
and 2002, and resource use was substantial.
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